| budesonide/formoterol / Generic mfg. |
| Not yet recruiting | 4 | 135 | | | Dr John D Brannan, GlaxoSmithKline | Asthma | | | | |
ACTRN12622000232730: Monitoring Intermittent vs Regular inhaled corticoSteroids in asthma: MIRSA study |
|
|
| Not yet recruiting | 4 | 135 | | | Dr John D Brannan, GlaxoSmithKline | Asthma | | | | |
NCT00479739: CONCEPT: A 1-Year Comparison Of A Stable Dose Of SERETIDE® Inhaler With An Adjustable Maintenance Dose Of SYMBICORT® Inhaler. SERETIDE® Inhaler is a Trademark of GSK Group of Companies. SYMBICORT® Inhaler is a Trademark of Astra Zeneca. |
|
|
| Completed | 4 | 700 | Canada, Europe, RoW | Salmeterol/fluticasone propionate or formoterol/budesonide | GlaxoSmithKline | Asthma | 07/04 | 07/04 | | |
NCT00272753: Effect of Budesonide / Formoterol Combination in Repeated AMP Provocations |
|
|
| Completed | 4 | 20 | Europe | budesonide/formoterol Turbuhaler, Symbicort, formoterol Turbuhaler, salbutamol | AstraZeneca | Asthma | | 11/05 | | |
2005-005874-65: Non-invasive monitoring of airway inflammation in asthmatic patients during adaptation of inhaled steroid therapy |
|
|
| Ongoing | 4 | 40 | Europe | Symbicort Turbohaler, Inhalation powder | University Hospital Antwerp | asthma | | | | |
NCT00242411 / 2004-000679-32: MONO: Symbicort® Single Inhaler Therapy and Conventional Best Standard Treatment for the Treatment of Persistent Asthma in Adolescents and Adults |
|
|
| Completed | 4 | 1900 | Europe | Budesonide/Formoterol Turbuhaler, Conventional Best Asthma Therapy | AstraZeneca | Asthma | 10/06 | 10/06 | | |
SMARTER, NCT00576316: Symbicort Maintenance and Reliever Therapy - Experience in Real Life Setting in Malaysia |
|
|
| Completed | 4 | 201 | RoW | Symbicort Turbuhaler 160/4.5 | AstraZeneca | Asthma | | 11/08 | | |
WSMR2, NCT00915538: Comparing Bronchodilation of Symbicort With and Without Valved Holding Chamber (Aerochamber Plus) |
|
|
| Completed | 4 | 16 | US | pMDI budesonide/formotrol 160/4.5 is in group 1, Symbicort, Symbicort 160/4.5 plus Aerochamber Plus included in group 2, Aerochamber plus | Western Sky Medical Research, AstraZeneca | Asthma | 08/09 | 08/09 | | |
| Completed | 4 | 311 | US | Budesonide / formoterol fumarate (SYMBICORT), SYMBICORT, Budesonide, PULMICORT | AstraZeneca | Asthma | 09/09 | 09/09 | | |
NCT00867737: Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS) |
|
|
| Unknown status | 4 | 30 | US | Advair HFA MDI 115/21, Advair = fluticasone proprionate plus salmeterol, Symbicort 160/4.5 pMDI, Symbicort = budesonide plus formoterol fumarate | Allergy and Asthma Center of El Paso, GlaxoSmithKline | Asthma | 09/09 | 09/09 | | |
NCT00858286: A Follow-up Survey to Compare Stable Dosing (SERETIDE) With SYMBICORT, SMART, Maintenance and Reliever Therapy in One Inhaler in Moderate and Severe Asthmatics. |
|
|
| Completed | 4 | 56 | Europe | Spirometry, PEF measurements and diary cards to evaluate control of Asthma | GlaxoSmithKline | Asthma | 04/10 | 04/10 | | |
SMARTASIA, NCT00939341: Study to Investigate Real Life Effectiveness of Symbicort Maintenance and Reliever Therapy in Asthma Patients Across Asia |
|
|
| Completed | 4 | 862 | RoW | Symbicort (Budesonide/Formoterol), Symbicort | AstraZeneca | Asthma | 08/10 | 08/10 | | |
NCT01647646: Real Life Effectiveness in Patients With Not Optimally Controlled Asthma |
|
|
| Completed | 4 | 200 | RoW | Seretide, Symbicort compared with Seretide | Far Eastern Memorial Hospital | Asthma | 02/11 | 03/12 | | |
NCT01070888: Trial on the Effect of Budesonide/Formoterol and Inhaled Budesonide Alone on Exercise-Induced Asthma |
|
|
| Terminated | 4 | 6 | US | Budesonide/Formoterol, Symbicort, Budesonide, Pulmicort | Boston Children's Hospital, Brigham and Women's Hospital | Exercise Induced Asthma | 04/14 | 04/14 | | |
NCT01404013: Effects of Leukotriene Modulator Montelukast on Cough Variant Asthma |
|
|
| Unknown status | 4 | 99 | RoW | ICS/LABA, Symbicort Turbuhaler, Montelukast, Singulair, ICS/LABA and Montelukast, Inhaled corticosteroid/β2 agonist: Symbicort Turbuhaler, Montelukast: Singulair | The First Affiliated Hospital of Guangzhou Medical University, Merck Sharp & Dohme LLC | Asthma | 08/14 | 08/14 | | |
2008-006768-13: Follow-up survey for comparing stable dosing with a symptom based “as needed-regimen” in moderate and severe persitent asthma. |
|
|
| Completed | 4 | 100 | Europe | Seretide Diskus mite inhalationpowder pre-dispensed(50/100 mikrog) Seretide Diskus inhalationpowder pre-dispensed (50/250 mikrog) Seretide Diskus forte inhalationpowder pre-dispensed(50/500 mikrog), Symbicort forte Turbuhaler, inhalationpowder 320 microg/9 microg Symbicort mite Turbuhaler inhalationpowder 80 microg/4,5 microg Symbicort Turbuhaler inhalationpowder 160 mikrogram/4,5 microg, Seretide Diskus mite inhalationpowder pre-dispensed(50/100 mikrog) Seretide Diskus inhalationpowder pre-dispensed (50/250 mikrog) Seretide Diskus forte inhalationpowder pre-dispensed(50/500 mikrog), Symbicort forte Turbuhaler, inhalationpowder 320 microg/9 microg Symbicort mite Turbuhaler inhalationpowder 80 microg/4,5 microg Symbicort Turbuhaler inhalationpowder 160 mikrogram/4,5 microg | GlaxoSmithKline AB | Moderate and severe persistent asthma. | | 04/10 | | |
2008-005707-26: Effect of beclomethasone dipropionate/formoterol fumarate (BDP+FF) administered as a fixed pMDI combination on lung impedance and exhaled nitric oxide in comparison with the fixed combination of budesonide and formoterol fumarate (Symbicort Turbohaler®). FLEX study (Foster fixed combination on Lung Impedance and Exhaled nitric oXide)A single-centre, randomized, double blind, double-dummy, two-way cross-over, repeated dose study |
|
|
| Completed | 4 | 24 | Europe | Foster® 100/6, SYMBICORT® TURBOHALER® 160/4,5, CHF 1535 HFA pMDI, NA, FOSTER®, Symbicort® Turbohaler®, FOSTER®, Symbicort® Turbohaler® | Chiesi Farmaceutici SpA | Bronchial Asthma | | 05/10 | | |
NCT02233803: A Non-inferiority Study to Evaluate Efficacy, Safety and Tolerability of NEUMOTEROL® 400 and SYMBICORT® Forte in Adults With Asthma |
|
|
| Completed | 4 | 239 | RoW | NEUMOTEROL 400 (BFF 400/12 mcg) single capsule inhaler, SYMBICORT forte (BFF 320/9mcg) TURBUHALER inhaler, NEUMOTEX 400 (Budesonide 400 mcg), Salbutamol 100 mcg pMDI | GlaxoSmithKline | Asthma | 12/15 | 12/15 | | |
2014-001029-34: The inhaled combination of budesonide-formoterol consists a basic asthma treatment.A helpful specific index for the prognosis of future exacerbation risk and deterioration of lung function,is the Exhaled Nitric Oxide.The objective of the current study is the evaluation of Pulmoton- Elpenhaler in Exhaled Nitric Oxide of patients with bronchial asthma. Ο εισπνεόμενος συνδυασμός βουδεσονίδης-φοÏμοτεÏόλης αποτελεί τη βασική θεÏαπεία για το άσθμα. Ένας ειδικός δείκτης που βοηθά στην Ï€Ïόγνωση Î¼ÎµÎ»Î»Î¿Î½Ï„Î¹ÎºÎ¿Ï ÎºÎ¹Î½Î´Ïνου παÏόξυνσης και μείωσης της λειτουÏγίας των πνευμόνων, είναι το εκπνεόμενο μονοξείδιο του αζώτου.Η παÏοÏσα μελÎτη Îχει ως κÏÏιο σκοπό την αξιολόγηση της επίδÏασης του εισπνεόμενου ÏƒÏ…Î½Î´Ï…Î±ÏƒÎ¼Î¿Ï Î²Î¿Ï…Î´ÎµÏƒÎ¿Î½Î¯Î´Î·Ï‚-φοÏμοτεÏόλης (Pulmoton® Elpenhaler®) στο εκπνεόμενο μονοξείδιο του αζώτου ασθενών με βÏογχικό άσθμα. |
|
|
| Ongoing | 4 | 108 | Europe | Pulmoton/Elpenhaler, Symbicort Turbuhaler, Pulmoton/Elpenhaler (200/6)mcg, Symbicort Turbuhaler, Pulmoton/Elpenhaler (200/6)mcg, Symbicort Turbuhaler | ELPEN Pharmaceutical Co. Inc, ELPEN Pharmaceutical Co. Inc. | Bronchial Asthma BÏογχικό Άσθμα | | | | |
NCT02574975: Assessment of Airway Responsiveness and Treatment Efficacy in Asthmatics |
|
|
| Unknown status | 4 | 80 | RoW | methacholine, adenosine monophosphate, leukotriene D4, Astograph Jupiter-21 airway reaction testing apparatus, budesonide /formoterol, Symbicort | Zhujiang Hospital | Asthma | 05/16 | 05/16 | | |
NCT02934945: Treatment Efficacy of Budesonide/Formoterol in Cough Variant Asthma and Typical Asthma Patients |
|
|
| Unknown status | 4 | 30 | RoW | budesonide 160μg/formoterol 4.5μg, Symbicort | Zhujiang Hospital | Bronchial Asthma | 01/17 | 03/17 | | |
NCT03563001: Differences of Small Airways Function Between Chronic Obstructive Pulmonary Disease(COPD) and Asthma-copd Overlap(ACO) |
|
|
| Unknown status | 4 | 80 | RoW | Budesonide(160ug) and Formoterol(4.5ug) bid, SYMBICORT TURBUHALER | Zhujiang Hospital | Pulmonary Disease, Chronic Obstructive, Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome, Small Airway Disease, Quality of Life | 09/18 | 09/18 | | |
2018-003467-64: A 24-week Study aiming to characterise changes in airway inflammation, symptoms, lung function, and reliever use in asthma patients using Salbutamol or AntiInflammatory Reliever (SYMBICORT®) as rescue medication in addition to SYMBICORT as daily asthma controller. |
|
|
| Not yet recruiting | 4 | 80 | Europe | Symbicort® Turbohaler® 100 micrograms/6 micrograms/inhalation, Symbicort® Turbohaler® 200 micrograms/6 micrograms/inhalation, Inhalation powder, Symbicort® Turbohaler® | Astra Zeneca AB, Astra Zeneca AB | Asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
NCT03788395: The Use of an Innovative Device for Therapeutic Adherence in Pediatric Asthma |
|
|
| Completed | 4 | 18 | Europe | Symbicort Turbohaler plus Turbo+, Symbicort Turbohaler without Turbo+ | Istituto per la Ricerca e l'Innovazione Biomedica | Asthma | 01/20 | 01/20 | | |
ChiCTR1800020279: Clinical trial for step-down therapy in patients with mild to moderate asthma |
|
|
| Recruiting | 4 | 100 | | budenide 200μg qd+SABA prn ;symbicort 80/4.5μg qd+prn ;symbicort 80/4.5μg prn ;symbicort 80/4.5μg prn ;SABA prn | West China Hospital, Sichuan University; West China Hospital, Sichuan University, latitudinal project funds | bronchial asthma | | | | |
NCT03924635: An Exploratory Study to Characterise Changes in Airway Inflammation, Symptoms, Lung Function and Reliever Use in Adult Asthma Patients |
|
|
| Completed | 4 | 40 | Europe | SYMBICORT and salbutamol, VENTOLIN (salbutamol), SYMBICORT (budesonide/formoterol) | AstraZeneca | Airway Inflammation, Asthma | 12/22 | 12/22 | | |
NCT01225913: Mechanism(s) of Airflow Limitation During Exacerbation of Asthma |
|
|
| Recruiting | 4 | 50 | US | fluticasone/salmeterol in all asthmatics, symbicort 80/4.5, advair 100/50 or 250/50 or 500/50 bid, budesonide/formoterol or fluticasone/salmeterol in all asthmatics, symbicort 160/4.5, advair 250/50 | Gelb, Arthur F., M.D. | Asthma | 06/27 | 06/27 | | |
